Press releases

All Press releases are available in Swedish.

November 06, 2017
Regulatory

Cyxone has analysed the Rabeximod that was previously manufactured by OxyPharma for clinical trials at Syntagon AB. Results show that the existing substance, despite having been stored for several years, can be used in Cyxone's upcoming Phase 2b study in patients with rheumatoid arthritis.

Read more
October 26, 2017
Regulatory

Summary

Period (July 1 to September 30, 2017)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -1,518 (-1,235)
  • Earnings per share SEK -0,10 (-0,10) Cash and cash equivalents as of September 30 KSEK 25,662 (23,468)
  • Equity ratio as of September 30 95.2% (97.7%)

Period (January 1 to September 30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -5,593 (-2,860)
  • Earnings per share SEK -0,36 (-0,22)
Read more
October 26, 2017
Regulatory
In co-operation with Taiwan-based Eurofins Panlabs Discovery Services, Cyxone has investigated whether T20K has the capacity to influence receptors or other cellular functions to shed light on the substance's potential side effects.
Read more
October 13, 2017
Regulatory

In collaboration with the Medical University of Vienna, Cyxone is set to conduct a study into inflammatory bowel disease involving a cyclotide in established animal models. The study will begin early in 2018.

Read more
October 06, 2017
Regulatory

Cyxone has licensed patent applications at various stages of approval in Europe, North America and Australia. In the US, our patent is approved and in other markets patent applications are well on the way to being approved. In Australia, our patent application was accepted in July, since when the company has submitted a final version and paid the required approval fee. 

Read more
October 05, 2017
Regulatory

Due to the interview conducted with Cyxone's CEO by BioStock/Monocl on Thursday, September 28, the company wishes to clarify references made about the extent to which two Phase 2 trials may be equated with a Phase 3 trial.

Read more
October 05, 2017
Regulatory

The subscription period to purchase warrants in TO 2 ended on September 29, 2017, and during the period, 2,467,119 warrant options were exercised for the equivalent number of shares, corresponding to a subscription ratio of around 98.7%. Cyxone thereby receives some SEK 12.3 million before issue costs.

Read more
August 30, 2017
Regulatory

Summary of interim report

Period (2017-01-01-2017-06-30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -4 075 (-1 626)
  • Earnings per share -0,27 (-0,13) SEK
  • Cash and cash equivalents, KSEK 28 114 (24 636) as of 2017-06-30
  • Equity ratio 95,2 (87,9) % as of 2017-06-30

Period (2017-04-01-2017-06-30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -2 588 (-1 157)
  • Earnings per share SEK -0,17 (-0,09) 
Read more
May 16, 2017
Regulatory

Period (2017-01-01-2017-03-31)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -1491 (-307)
  • Earnings per share -0,10 (-0,04) SEK
  • Cash and cash equivalents (2017-03-31) 31 275 (4 114) KSEK
  • Equity ratio 98,2 (97,8) % as of 2017-03-31
Read more
March 10, 2017
Regulatory

Cyxone can announce today that an independent research group at Monash University in Australia has confirmed the positive effects of the company's development substance T20K on multiple sclerosis (MS) symptoms in animal models as previously described.

Read more
1
2